Rick Soni is the President and Chief Operating Officer of Rexahn Pharmaceuticals, a publically-traded clinical stage biopharmaceutical company. He has held this position since August, 2009. Prior to that, he also served as Chief Business Officer from July 2008 to August 2009. While at Rexahn, Mr. Soni has been instrumental in transforming Rexahn from a discovery stage company to a clinical stage company and has formed a major licensing partnership between Rexahn and Teva Pharmaceuticals.
Prior to joining Rexahn, Mr. Soni held various management positions within Otsuka from June 1997 until July 2008 and was responsible for development and commercialization of otsuka’s successful product portfolio. Prior to Otsuka, Mr. Soni also held several management roles within New Product Planning, Sales and Marketing at Novartis and Schering-Plough (now Merck).
Mr. Soni received his undergraduate degree in Industrial Engineering from University of Wisconsin- Madison and an MBA from Fairleigh Dickinson University.